IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4573
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$120M
Thomas Butler
Biomea Fusion, Inc. focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$BMEA Biomea Fusion, Inc. | 29 | 25 | 32 | 19 | - | - | -635.1% | -179.8% | - | -3681.7% | -3581.7% | - | 0.0% | 253.0x | $120M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Biomea Fusion, Inc. (BMEA) receives a "Avoid" rating with a composite score of 29.2/100. It ranks #4573 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Thomas Butler
Chief Executive Officer
Labor Force
50
25
25
30
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for BMEA
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for BMEA.
View All RatingsInsufficient data for Financial Analysis
ROE proxy -635.1% (sector -2.5%)
GM N/A vs sector 43%, OM -3682% vs sector 1%
Capital turnover N/A, R&D intensity 1000.4%
Rev growth N/A, 5yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags Biomea Fusion, Inc. with an Avoid rating, assigning a composite score of 29.2/100 and 1 out of 5 stars. Ranked #4573 of 7,333 stocks, BMEA falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
BMEA's quality score of 25/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -635.1% (sector avg: -2.5%), net margins of -3581.7% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 32/100, BMEA appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 5.98x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Biomea Fusion, Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -179.8% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Biomea Fusion, Inc. is experiencing notably weak momentum with a score of just 19/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth data is not currently available, while a beta of 1.43 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
BMEA's stability score of 30/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.43 and a debt-to-equity ratio of 253.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Biomea Fusion, Inc.'s short interest score of 20/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.43), elevated leverage (D/E: 253.00x), micro-cap liquidity risk. At $120M (micro-cap), BMEA carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Biomea Fusion, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4573 of 7,333 overall (38th percentile). Key comparisons include ROE of -635.1% trailing the -2.5% sector median and operating margins of -3681.7% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While BMEA currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (19) would have the largest impact on the composite score.
ROE 25509% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 285504% BELOW SECTOR MEDIAN
Debt/Equity 126400% ABOVE SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Biomea Fusion, Inc. (BMEA) as Avoid with a composite score of 29.2/100 at a current price of $1.30. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in value (32th percentile) and stability (30th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (19th percentile) and quality (25th percentile) tempers our overall conviction. We assign a No Moat rating (20/100), Very High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; balance sheet deleveraging progress; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Biomea Fusion, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 29.2/100 places it at rank #4573 in our full 7,333-stock universe. At $120M in market capitalization, Biomea Fusion, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (19th percentile) suggest caution regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Available margin data shows operating margins of -3682%. Incomplete margin data limits our ability to fully assess the cost structure and margin trajectory, though the available metrics provide a partial view of operating efficiency.
At a current price of $1.30, Biomea Fusion, Inc. is trading at a premium to fundamental value. Our value factor score of 32/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 6.0x, P/S of 17.3x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
The stock may offer contrarian value if near-term headwinds prove transitory — the current weakness in factor scores may reverse if business fundamentals stabilize.
The Avoid rating (composite 29.2/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Elevated leverage (253% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
Thin net margins of -3581.7% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Weak momentum (19th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
We assign a Very High uncertainty rating to Biomea Fusion, Inc.. The stock exhibits multiple compounding risk factors: elevated market sensitivity (beta of 1.43), significant leverage (253% debt-to-equity), current negative profitability (net margin -3581.7%). The extreme uncertainty around future cash flows makes precise valuation difficult, and the range of outcomes is exceptionally wide. Only investors with high risk tolerance and extended time horizons should consider this name.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 1.43); significant leverage (253% debt-to-equity); current negative profitability (net margin -3581.7%); below-average price stability (30th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 30th percentile and quality factor at the 25th percentile provide a quantitative summary of the overall risk landscape.
We identify limited risk mitigants at this time, which contributes to our very high uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate Biomea Fusion, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-635.1%), elevated leverage (253% D/E), negative profitability, weak asset returns (ROA -179.8%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Biomea Fusion, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Biomea Fusion, Inc. receives a Avoid rating with a composite score of 29.2/100 (rank #4573 of 7,333). Our quantitative framework assigns a No Moat (20/100, trend: stable), Very High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 26/100.
Our analysis does not support a constructive view on Biomea Fusion, Inc. at this time. The combination of limited competitive advantages, very high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Biomea Fusion, Inc. a meaningful economic moat, scoring 20/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, reinvestment efficiency, reached only 7/20.
The strongest moat sources are reinvestment efficiency (7/20) and margin superiority (6.5/20). Capital turnover N/A, R&D intensity 1000.4%. GM N/A vs sector 43%, OM -3682% vs sector 1%. These pillars form the core of Biomea Fusion, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include growth durability (1.4/20) and economic value creation (2.5/20). Rev growth N/A, 5yr history. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Biomea Fusion, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers are not clearly identifiable from current fundamentals. This may reflect a company in transition, a cyclical downturn, or structural challenges in the business model. We assign a quality factor of 25/100 which further underscores our concern regarding earnings sustainability.
The margin profile shows operating margins of -3682%, net margins of -3581.7%. Return metrics include ROE of -635.1% and ROA of -179.8%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of -635.1% compares to a sector median of -2.5%.
The balance sheet reflects high leverage with D/E of 253%, which may limit financial flexibility. The sector median D/E is 0%, putting Biomea Fusion, Inc. at higher leverage than the typical peer. Elevated leverage in combination with the current margin profile warrants close monitoring for any deterioration in debt-servicing capacity.
Below-average quality (25th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
Above 50MA
37.18%
Net New Highs
+51081
SAN CARLOS, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference: Biomea will present virtually on February 26, 2026, at 10:00 AM (EDT). Company management will also meet with investors in one-on-one meetings during the conference.
Biomea Fusion Inc. (NASDAQ:BMEA) is one of the overlooked growth stocks to buy. On January 14, Rodman & Renshaw initiated coverage of Biomea Fusion with a Buy rating and $8 price target. In Q3 2025, Biomea announced that the company was shifting its strategy to focus on its two primary assets: icovamenib, a menin inhibitor […]
Biomea Fusion reported a reduced net loss of $20.7 million in Q2 2025, down from $37.3 million in the same period of 2024. The biotechnology company focused on metabolic disease treatments showed progress in cost management and clinical development of its lead drug icovamenib for diabetes and potential obesity treatments.
Biomea Fusion, a clinical-stage diabetes and obesity company, announced a proposed public offering of its common stock and warrants. The offering is subject to market conditions and is expected to close on or around June 20, 2025.